Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.64 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794825 | 0.87 | HCRTR1 (0.58) | HCRTR1HCRTR2MAPTALDH1A1 | |
| SCHEMBL6787462 | 0.87 | HCRTR1 (0.80) | HCRTR1HCRTR2MAPTPDE4APDE4B | |
| SCHEMBL6788253 | 0.86 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL6788800 | 0.86 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL6376211 | 0.82 | HCRTR1 (0.50) | HCRTR1HCRTR2MAPTMEN1KMT2A | |
| SCHEMBL6375167 | 0.81 | HCRTR1 (0.60) | HCRTR1HCRTR2MAPTMEN1KMT2A | |
| SCHEMBL6787308 | 0.80 | HCRTR1 (0.84) | HCRTR1HCRTR2 | |
| SCHEMBL6792342 | 0.80 | HCRTR1 (0.78) | HCRTR1HCRTR2MAPTSMN1; SMN2 | |
| SCHEMBL6789132 | 0.80 | HCRTR1 (0.78) | HCRTR1HCRTR2MAPTSMN1; SMN2 | |
| SCHEMBL6787109 | 0.78 | HCRTR1 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885MAPT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.